Annick D Van den Abbeele

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression
    Annick D Van den Abbeele
    Department of Imaging, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Nucl Med 53:567-74. 2012
  2. ncbi Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs)
    Annick D Van den Abbeele
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    Eur J Cancer 38:S60-5. 2002
  3. doi The lessons of GIST--PET and PET/CT: a new paradigm for imaging
    Annick D Van den Abbeele
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Oncologist 13:8-13. 2008
  4. pmc Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure
    George D Demetri
    Center for Sarcoma and Bone Oncology, Ludwig Center at Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:5902-9. 2009
  5. pmc Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial
    Suzanne George
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute D1212, 450 Brookline Ave, Boston, MA, USA
    J Clin Oncol 30:2401-7. 2012
  6. doi Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib
    Katherine A Janeway
    Pediatric Oncology, Dana Farber Cancer Institute and Department of Medicine, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    Pediatr Blood Cancer 52:767-71. 2009
  7. doi Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell ca
    Katherine M Krajewski
    Department of Imaging, Dana Farber Cancer Institute, Boston, MA, USA
    Eur Urol 59:856-62. 2011
  8. pmc New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy
    Mizuki Nishino
    Department of Radiology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02116, USA
    AJR Am J Roentgenol 195:W221-8. 2010
  9. pmc Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center
    Atul B Shinagare
    Department of Imaging, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 117:3860-6. 2011
  10. pmc Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas
    Suzanne George
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
    J Clin Oncol 27:3154-60. 2009

Detail Information

Publications43

  1. pmc ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression
    Annick D Van den Abbeele
    Department of Imaging, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Nucl Med 53:567-74. 2012
    ....
  2. ncbi Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs)
    Annick D Van den Abbeele
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    Eur J Cancer 38:S60-5. 2002
    ....
  3. doi The lessons of GIST--PET and PET/CT: a new paradigm for imaging
    Annick D Van den Abbeele
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Oncologist 13:8-13. 2008
    ....
  4. pmc Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure
    George D Demetri
    Center for Sarcoma and Bone Oncology, Ludwig Center at Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:5902-9. 2009
    ....
  5. pmc Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial
    Suzanne George
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute D1212, 450 Brookline Ave, Boston, MA, USA
    J Clin Oncol 30:2401-7. 2012
    ....
  6. doi Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib
    Katherine A Janeway
    Pediatric Oncology, Dana Farber Cancer Institute and Department of Medicine, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    Pediatr Blood Cancer 52:767-71. 2009
    ..Sunitinib prolongs survival in adult patients with imatinib-resistant gastrointestinal stromal tumor (GIST). We report the experience with sunitinib in pediatric patients with advanced GIST following failure of imatinib...
  7. doi Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell ca
    Katherine M Krajewski
    Department of Imaging, Dana Farber Cancer Institute, Boston, MA, USA
    Eur Urol 59:856-62. 2011
    ..Since these therapies can induce tumor necrosis and minimal tumor shrinkage, Response Evaluation Criteria in Solid Tumors (RECIST) may not be optimal for predicting clinical outcome...
  8. pmc New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy
    Mizuki Nishino
    Department of Radiology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02116, USA
    AJR Am J Roentgenol 195:W221-8. 2010
    ..1) to the original guidelines (RECIST 1.0) for advanced non-small cell lung cancer (NSCLC) after erlotinib therapy and to evaluate the impact of the new CT tumor measurement guideline on response assessment...
  9. pmc Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center
    Atul B Shinagare
    Department of Imaging, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 117:3860-6. 2011
    ..The purposes of the current study is to determine the incidence of PE in oncology outpatients and to investigate whether the incidence for PE is higher in certain cancers...
  10. pmc Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas
    Suzanne George
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
    J Clin Oncol 27:3154-60. 2009
    ....
  11. ncbi Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors
    Jayesh Desai
    Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 13:5398-405. 2007
    ..The objective of this study was to correlate molecular and radiologic patterns of imitinib-refractory disease with existing conventional criteria for disease progression...
  12. doi Major response to imatinib mesylate in KIT-mutated melanoma
    F Stephen Hodi
    The Melanoma Program, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 26:2046-51. 2008
  13. pmc Imaging of lung cancer in the era of molecular medicine
    Mizuki Nishino
    Department of Imaging, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Acad Radiol 18:424-36. 2011
    ..Knowledge of the molecular basis of lung cancer is essential for radiologists to properly interpret imaging and assess response to therapy. Quantitative and functional imaging helps assessing the biologic behavior of lung cancer...
  14. doi Imaging of extraosseous myeloma: CT, PET/CT, and MRI features
    Matthew N Hall
    Department of Radiology, Brigham and Women s Hospital, Boston, MA, USA
    AJR Am J Roentgenol 195:1057-65. 2010
    ..CONCLUSION: The presence of radiologically detectable extraosseous myeloma is associated with a poor prognosis and thus is an important factor in the initial workup and follow-up evaluation...
  15. doi Hereditary cancer syndromes: a radiologist's perspective
    Atul B Shinagare
    Department of Imaging, Dana Farber Cancer Institute, Boston, MA, USA
    AJR Am J Roentgenol 197:W1001-7. 2011
    ..The purpose of this article is to present the important malignancies associated with the most common hereditary cancer syndromes...
  16. doi Adult extragonadal germ cell tumors
    Atul B Shinagare
    Department of Imaging, Dana Farber Cancer Institute, Boston, MA 02115, USA
    AJR Am J Roentgenol 195:W274-80. 2010
    ..Levels of human chorionic gonadotropin or ╬▒-fetoprotein or both may be elevated, depending on the histologic subtype...
  17. doi Atypical metastases from prostate cancer: 10-year experience at a single institution
    Anant H Vinjamoori
    Department of Imaging, Dana Farber Cancer Institute Brigham and Women s Hospital, Harvard Medical School, 450 Brookline Ave, Boston, MA 02115, USA
    AJR Am J Roentgenol 199:367-72. 2012
    ....
  18. doi Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis
    Alfred Ian Lee
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02114, USA
    Cancer 116:3835-42. 2010
    ..The majority of patients with Hodgkin lymphoma (HL) achieve disease remission after primary therapy. To the best of the authors' knowledge, no consensus exists for postremission surveillance imaging...
  19. doi Urothelial cancers of the upper urinary tract: metastatic pattern and its correlation with tumor histopathology and location
    Atul B Shinagare
    Department of Imaging, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Comput Assist Tomogr 35:217-22. 2011
    ..To study the metastatic pattern of upper urinary tract urothelial cancer and to correlate it with tumor histopathology and location...
  20. doi Evaluation of low-density neutral oral contrast material in PET/CT for tumor imaging: results of a randomized clinical trial
    Hansel J Otero
    Department of Radiology, Brigham and Women s Hospital, 1620 Tremont St, 3rd Fl, Radiology Ste, Boston, MA 02120, USA
    AJR Am J Roentgenol 193:326-32. 2009
    ....
  21. doi Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know
    Mizuki Nishino
    Department of Imaging, Dana Farber Cancer Institute, Boston, MA 02115, USA
    AJR Am J Roentgenol 195:281-9. 2010
    ..Some of the changes in the revised RECIST affect how radiologists select, measure, and report target lesions...
  22. doi Imaging in renal cell carcinoma
    Katherine M Krajewski
    Department of Imaging, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Hematol Oncol Clin North Am 25:687-715. 2011
    ..Future directions in RCC imaging are presented, including dynamic contrast-enhanced and unenhanced techniques, as well as the development of novel tracers for positron emission tomography...
  23. doi F-18 FDG PET/CT in the diagnosis and management of a pericardiac paraganglioma
    Niall Sheehy
    Department of Radiology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Clin Nucl Med 33:545-6. 2008
  24. doi CT and PET/CT findings of T-cell lymphoma
    Hansel J Otero
    Department of Radiology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    AJR Am J Roentgenol 193:349-58. 2009
    ..The purpose of this study was to describe the extranodal features of T-cell lymphoma at CT and PET/CT...
  25. ncbi Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
    George D Demetri
    Dana Farber Cancer Institute and Harvard Cancer Center, Boston, MA 02115, USA
    N Engl J Med 347:472-80. 2002
    ..Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors...
  26. ncbi Impact of acquisition geometry, image processing, and patient size on lesion detection in whole-body 18F-FDG PET
    Georges El Fakhri
    Division of Nuclear Medicine, Department of Radiology, Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Nucl Med 48:1951-60. 2007
    ..In all patients, RVR yielded a systematic improvement in CHO-SNR over DWS in both 2D and 3D. radicalNEC was characterized by a behavior similar to that of SNR(CHO) for the 3 different phantom sizes considered in this study...
  27. doi F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome
    Serena Masciari
    Division of Population Sciences, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    JAMA 299:1315-9. 2008
    ..The diversity of tumors and rarity of families have contributed to the difficulty in devising effective screening recommendations for members of LFS kindreds...
  28. doi Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET
    Lia M Halasz
    Harvard Radiation Oncology Program, Boston, Massachusetts, USA
    Int J Radiat Oncol Biol Phys 83:e647-54. 2012
    ..To evaluate outcomes of patients treated for aggressive non-Hodgkin lymphoma (NHL) with combined modality therapy based on [(18)F]fluoro-2-deoxy-2-d-glucose positron emission tomography (FDG-PET) response...
  29. ncbi Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer
    A David McCollum
    Dana Farber Cancer Institute, Department of Medical Oncology, Boston, Massachusetts, USA
    Head Neck 26:890-6. 2004
    ....
  30. pmc CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool
    Mizuki Nishino
    Department of Imaging, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA 02115, USA
    Acad Radiol 18:54-62. 2011
    ..Determine inter- and intraobserver variability of computed tomography (CT) tumor volume measurements in advanced non-small-cell lung cancer (NSCLC) patients treated in a Phase II clinical trial using chest CT...
  31. pmc Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
    Tammy F Chu
    Department of Cardiology, Children s Hospital Boston and Harvard Medical School, Boston, MA 02115, USA
    Lancet 370:2011-9. 2007
    ..We therefore assessed the cardiovascular risk associated with sunitinib in patients with metastatic gastrointestinal stromal tumours...
  32. doi Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw
    Noopur Raje
    The Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02114, USA
    Clin Cancer Res 14:2387-95. 2008
    ..Osteonecrosis of the jaw (ONJ) has been reported in patients with a history of aminobisphosphonate use. This study was conducted in order to define ONJ clinically and radiographically and gain insights into its pathophysiology...
  33. doi Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor
    Atul B Shinagare
    Department of Imaging, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    AJR Am J Roentgenol 196:117-22. 2011
    ..The purpose of this study was to evaluate the metastatic pattern of muscle-invasive bladder cancer and to correlate the findings with the characteristics of the primary tumor...
  34. doi Venous thrombosis in an outpatient oncologic center: distribution, type, and comorbidities
    Frederico F Souza
    Department of Radiology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Ultrasound Q 25:145-50. 2009
    ..To examine outpatient oncologic patients with venous thrombosis (VT) and correlate ultrasound findings with clinical characteristics and outcome...
  35. ncbi Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas
    John V Heymach
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Clin Cancer Res 10:5732-40. 2004
    ..This Phase II study was conducted to investigate the safety and efficacy of SU5416 for patients with soft tissue sarcomas...
  36. doi Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
    Nancy U Lin
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:1993-9. 2008
    ..We evaluated the safety and efficacy of lapatinib, an oral inhibitor of epidermal growth factor receptor (EGFR) and HER-2, in patients with HER-2-positive brain metastases...
  37. ncbi 2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography of the head and neck: an atlas of normal uptake and variants
    Steven C Burrell
    QE II Health Sciences Centre, Dalhousie Medical School, Halifax, Nova Scotia, Canada
    Mol Imaging Biol 7:244-56. 2005
    ..To assist in this endeavor, a pictorial of normal FDG uptake, including commonly encountered variants, is presented...
  38. ncbi NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines
    George D Demetri
    J Natl Compr Canc Netw 5:S1-29; quiz S30. 2007
    ....
  39. ncbi Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
    Michael C Heinrich
    R and D 19 3710 SW US Veterans Hospital Rd, Portland, OR 97207, USA
    J Clin Oncol 21:4342-9. 2003
    ..The relationship between mutations in these kinases and clinical response to imatinib was examined in a group of patients with advanced GIST...
  40. ncbi Role of PET/CT scanning in initial and post-treatment assessment of Hodgkin disease
    Sukru Mehmet Erturk
    Department of Radiology, Sisli Etfal Training and Research Hospital, Istanbul, Turkey
    J Natl Compr Canc Netw 6:623-32. 2008
    ..This article reviews the use of these imaging modalities in the initial staging and post-treatment assessment of Hodgkin disease...
  41. ncbi Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer
    Roy S Herbst
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 13:6175-81. 2007
    ..Based on supporting preclinical studies, we undertook a Phase II trial of pertuzumab in patients with recurrent non-small cell lung cancer (NSCLC)...
  42. ncbi CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor
    Clay H Holdsworth
    Massachusetts College of Pharmacy and Health Sciences, 4 Brook Rd, Unit 11, Salem, NH 03079, USA
    AJR Am J Roentgenol 189:W324-30. 2007
    ....
  43. ncbi FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    Leuk Lymphoma 45:85-92. 2004
    ..However, more patients have persistently positive PET at the end of chemotherapy compared with gallium (P = 0.04), although only half of these patients have relapsed...